February 2019 FDA Recall Drug by Mylan Pharmaceuticals Inc.
D-0506-2019 - Failed Impurities/Degradation Specifications
This Class III drug recall was voluntarily initiated by Mylan Pharmaceuticals Inc. on February 13, 2019 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed in Throughout the United States and the recall is currently terminated.
Recall Number: D-0506-2019
Failed Impurities/Degradation Specifications: High out of specification results obtained during routine stability testing
02-13-2019
02-27-2019
8,159 bottles
Recall Profile & Regulatory Data
Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Mylan Pharmaceuticals Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Throughout the United States
09-12-2019
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Diltiazem HCl Extended-Release Capsules, USP 180mg, Packaged in a) 100-count bottles (NDC 0378-5280-01), and b) 500-count bottles (NDC 0378-5280-05), Rx only, Manufactured by: Mylan Pharmaceuticals Inc. Morgantown, WV, 26505
Batch or Lot Expiration Information
Lot# : 3090167, Exp. October 2019